My ePortfolio Register   

REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 455
Rating:

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

Dr Topp speaks with ecancer at the 2017 ASH annual meeting about safety and preliminary anti-tumour activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies. 

He discusses the construction and current clinical utility of BiTE therapies, detailing the dose escalation studies of a novel anti-CD20 x anti-CD3 bispecific antibody, and notes the tolerability as assessed by MRD status.

Combination REGN2810 with REGN1979 has been well tolerated, and evaluation of the combination with higher REGN1979 doses continues.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence